,,ii  #aacth ,,congress  #ast ,session  
,s4 #acc  ,,in ,,the ,,senate ,,of ,,the
 ,,united ,,states  ,january #bd        
7legislative day1 ,january #c71 #bjac   
,mr4 ,roberts 7for himself1 ,mr4        
,coburn1 ,mr4 ,barrasso1 ,mr4 ,portman1 
,mr4 ,crapo1 ,mr4 ,inhofe1 and ,mr4     
,vitter7 introduced the following bill2 
which was read twice and referred to the
 ,committee on ,health1 ,education1     
,labor1 and ,pensions  ,a ,,bill  ,to   
protect all patients by prohibiting the 
use of data obtained from comparative   
effectiveness research to deny or delay 
coverage of items or services under     
,federal health care programs and to    
ensure that comparative effectiveness   
research accounts for advancements in   
personalized medicine and differences in
 patient treatment response4  #a4 ,short
 title ,this ,act may be cited as the   
,preserving ,access to ,targeted1       
,individualized1 and ,effective ,new    
,treatments and ,services 7,,patients7  
,act of #bjac or the ,,patients ,act of 

#bjac4  #b4 ,prohibition on ,certain    
,uses of ,data ,obtained from           
,comparative ,effectiveness ,research2  
,accounting for ,personalized ,medicine 
and ,differences in ,patient ,treatment 
,response  7a7 ,in general              
,notwithstanding any other provision of 
law1 the ,secretary of ,health and      
,human ,services--  7#a7 shall not use  
data obtained from the conduct of       
comparative effectiveness research1     
including such research that is         
conducted or supported using funds      
appropriated under the ,american        
,recovery and ,reinvestment ,act of     
#bjji 7,public ,law #aaa-e7 or          
authorized or appropriated under the    
,patient ,protection and ,affordable    
,care ,act 7,public ,law #aaa-adh71 to  
deny or delay coverage of an item or    
service under a ,federal health care    
program 7as defined in section          
#aabh;,b7f7 of the ,social ,security    
,act 7#db ,u4,s4,c4 #acbj;a-#g;b7f7772  
and  7#b7 shall ensure that comparative 

effectiveness research conducted or     
supported by the ,federal ,government   
accounts for factors contributing to    
differences in the treatment response   
and treatment preferences of patients1  
including patient-reported outcomes1    
genomics and personalized medicine1 the 
unique needs of health disparity        
populations1 and indirect patient       
benefits4  7b7 ,rule of construction    
,nothing in this section shall be       
construed as affecting the authority of 
the ,commissioner of ,food and ,drugs   
under the ,federal ,food1 ,drug1 and    
,cosmetic ,act or the ,public ,health   
,service ,act4